Takeda's Ninlaro Drug Overview 2019 with Sales by Country (2017-2026) - ResearchAndMarkets.com

DUBLIN--()--The "Ninlaro" report has been added to ResearchAndMarkets.com's offering.

Ninlaro (ixazomib; Takeda) reversibly inhibits the 20S proteasome, resulting in the accumulation of proteins and eventually leading to the activation of apoptotic pathways.

Preclinical studies suggest that Ninlaro demonstrates a stronger anti-tumor effect than Velcade (bortezomib; Takeda/Johnson & Johnson).

Key Topics Covered

  1. Drug Overview
  2. Product Profiles
  3. Ninlaro : Multiple myeloma

List of Figures

Figure 1: Ninlaro for multiple myeloma - SWOT analysis

Figure 2: The authors drug assessment summary of Ninlaro for multiple myeloma

Figure 3: Ninlaro sales for multiple myeloma across the US, Japan, and five major EU markets, by country, 2017-26

List of Tables

Table 1: Ninlaro drug profile

Table 2: Ninlaro pivotal trial data in multiple myeloma

Table 3: Ninlaro ongoing late-phase clinical trials in multiple myeloma

Table 4: Ninlaro sales for multiple myeloma across the US, Japan, and five major EU markets, by country ($m), 2017-26

Table 5: Patients treated with Ninlaro across the US, Japan, and five major EU markets, by country, 2017-26

For more information about this report visit https://www.researchandmarkets.com/r/yjixj3

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Leukemia Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Leukemia Drugs